ApexRx company profile: what is public, what is not

As of June 2026, ApexRx's public site does not disclose who owns the company, the names of its leadership, whether it has raised outside funding, where it is headquartered, or how many clinics use it. It also does not publish the specific 503A partner pharmacies it routes to or aggregate order volumes. Where a fact is not in ApexRx's public materials, it is undisclosed rather than estimated here.

This is common for privately held B2B platforms and is not, by itself, a red flag. But it does mean a clinic's due diligence has to come from direct requests rather than the website. The absence of public corporate detail simply shifts where you get your answers.

Because the corporate facts are not public, request them in the sales conversation: ask which legal entity you are contracting with, who stands behind the platform, and how long it has operated. Ask for the specific 503A partner pharmacies your clinic would route to and proof of their LegitScript certification and state licensure, since the platform's legitimacy ultimately rests on its partners. Ask for references from clinics like yours, and read the contract and cancellation terms before signing.

On the parts you can verify yourself, confirm the platform is a B2B clinic ordering tool at apexrx.co with email support at support@apexrx.co, and that pricing arrives through a custom quote. For a transparent point of comparison, Fizy Health publishes its model openly — pass-through per-vial 503A pricing before checkout, a disclosed facilitation fee, and LegitScript-certified partners — which is the kind of visibility to look for when a vendor's corporate details are thin.